



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

**Meeting to commence at 9.30 am on Tuesday 9th February 2021
(via Zoom)**

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of the previous meeting** 1/AWMSG/0221
5. **Chairman's verbal report**
6. **AWMSG Work Programme:** 2/AWMSG/0221
 - AWMSG Statements of Advice: review of process and engagement
 - Published article in Bio Drugs - A Look at the History of Biosimilar Adoption
7. **Feedback from AWPAG meeting held 2nd December 2020** 3/AWMSG/0221
8. **Best Practice Reminder - Avoid Nitrofurantoin in the Treatment of Pyelonephritis** 4/AWMSG/0221
9. **Shared Care Prescribing and Monitoring Guidance** 5/AWMSG/0221
10. **Prescribing Dilemmas (2020 Review)** 6/AWMSG/0221
11. **Safeguarding Users of Opioid Patches by Standardising Patient and Caregiver Counselling – for information** 7/AWMSG/0221
12. **Persistent pain resources – for information** 8/AWMSG/0221

To protect commercial confidentiality the following appraisals will be held in private and all observers will be asked to leave the meeting

13. **Appraisal 1: Full submission (Wales Patient Access Scheme)** 9/AWMSG/0221
Opicapone (Ongentys®) as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations
Enclosures
14. **Appraisal 2: Limited submission (Patient Access Scheme)**

Dupilumab (Dupixent®) for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy

10/AWMSG/0221
Enclosures

15. **Appraisal 3: Full submission (Wales Patient Access Scheme)**
Melatonin (Slenyto®) for the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient

11/AWMSG/0221
Enclosures

The outcome of the appraisals will be uploaded to the AWMSG website after the meeting. The applicant companies will have ten working days to accept the decision or lodge a request for a review which should be sent to the AWMSG Chair via AWTTTC. AWMSG's recommendation/s will be forwarded to Welsh Government for ratification following acceptance of the outcome by the applicant companies or after the ten day deadline has expired – whichever is sooner. Welsh Government will take into account the AWMSG recommendation when making the final decision on the availability of the medicine in NHS Wales.

Date of next meeting: Wednesday 10th March 2021 commencing 9.30 am